For NSCLC patients identified with one of these EGFR activating mutations, clinical response rates of approximately 75% have been observed with the administration of the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib [29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.